HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
Study sponsor: Altimmune, Inc. · ALT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-03-27Actual
Enrollment · participants87Actual
Source updated2025-12-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.